Mankind Pharma shares jumped 5% to Rs 2,333.90 on 26 Oct following a 39% surge in September quarter profit.

The board approved the numbers on 26 October. Consolidated net profit rose to Rs 711 crore, from Rs 512 crore a year earlier.

Sales grew too. Revenue from operations climbed 17.3% to Rs 4,338 crore, up from Rs 3,697 crore. The company also kept more of what it earned.

Its operating margin, the share of sales left after day-to-day costs, improved to about 27% from about 25% a year ago. Both home and overseas business pulled their weight.

Domestic revenue rose 15.9%, helped by double-digit growth in the Mankind and BSV specialty businesses, while international revenue jumped 33%.

During the quarter, Mankind introduced one new product in the US, bringing its total number of US launches to 50. The company also pointed to a recent purchase.

It bought Armed Cell Therapeutics, a move it described as its entry into CAR-T therapies, a newer class of treatment, and it said the deal strengthens its research work.

There was a housekeeping item as well. The board approved merging two wholly owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell, into one.

A wholly owned unit is one the parent fully controls. Mankind also filed an investor presentation with the exchange on 26 October.

Mankind Pharma closed at Rs 2,312 on NSE, up 4.49% from the previous close of Rs 2,212.60.

It’s up 6.81% so far this year but down 4.95% over one year, and its 52-week range runs from Rs 1,909.70 to Rs 2,642.

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!